TY - JOUR
T1 - Bone Cancer, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology
AU - Biermann, J. Sybil
AU - Hirbe, Angela
AU - Ahlawat, Shivani
AU - Bernthal, Nicholas M.
AU - Binitie, Odion
AU - Boles, Sarah
AU - Brigman, Brian
AU - Callan, Alexandra K.
AU - Cipriano, Cara
AU - Cranmer, Lee D.
AU - Davis, Jessica
AU - Donnelly, Eric
AU - Ferguson, Michael
AU - Graham, Ann
AU - Groundland, John
AU - Hess, Matthew
AU - Hiniker, Susan M.
AU - Hoover-Regan, Margo L.
AU - Hornick, Jason L.
AU - Jonard, Brandon
AU - Kuechle, Joseph B.
AU - Lindskog, Dieter
AU - Mayerson, Joel L.
AU - McGarry, Sean V.
AU - Morris, Carol D.
AU - Olson, Daniel
AU - Rose, Peter S.
AU - Santana, Victor M.
AU - Satcher, Robert L.
AU - Schwartz, Herbert
AU - Shulman, Rebecca M.
AU - Thorpe, Steven W.
AU - Wilky, Breelyn A.
AU - Wustrack, Rosanna L.
AU - Yoon, Janet
AU - Hang, Lisa E.
AU - Jones, Frankie
AU - Sansone, Nicholas
AU - Lyons, Megan
N1 - Publisher Copyright:
© 2025 Harborside Press. All rights reserved.
PY - 2025/4
Y1 - 2025/4
N2 - Ewing sarcoma and osteosarcoma constitute 36% of all primary bone cancers. However, these 2 subtypes represent the most commonly diagnosed bone cancer types in the pediatric and adolescent population. Although still largely unknown, certain genetic mutations, rearrangements, and/or predisposition syndromes likely play a role in the pathogenesis of bone cancer. Osteosarcoma may also develop as a direct result of the long-term side effects of radiation therapy. With the implementation of a multimodality approach to treatment, including multiagent neoadjuvant and adjuvant chemotherapy regimens, targeted therapy options, surgery, and radiation, individuals with Ewing sarcoma and osteosarcoma are showing higher cure rates and improved overall survival. The NCCN Guidelines for Bone Cancer provide a consensus and evidence-based framework for the workup, management, and surveillance of local and recurrent/metastatic disease.
AB - Ewing sarcoma and osteosarcoma constitute 36% of all primary bone cancers. However, these 2 subtypes represent the most commonly diagnosed bone cancer types in the pediatric and adolescent population. Although still largely unknown, certain genetic mutations, rearrangements, and/or predisposition syndromes likely play a role in the pathogenesis of bone cancer. Osteosarcoma may also develop as a direct result of the long-term side effects of radiation therapy. With the implementation of a multimodality approach to treatment, including multiagent neoadjuvant and adjuvant chemotherapy regimens, targeted therapy options, surgery, and radiation, individuals with Ewing sarcoma and osteosarcoma are showing higher cure rates and improved overall survival. The NCCN Guidelines for Bone Cancer provide a consensus and evidence-based framework for the workup, management, and surveillance of local and recurrent/metastatic disease.
KW - Bone Neoplasms/therapy
KW - Combined Modality Therapy/methods
KW - Humans
KW - Medical Oncology/standards
KW - Osteosarcoma/therapy
KW - Sarcoma, Ewing/therapy
UR - https://www.scopus.com/pages/publications/105002481152
U2 - 10.6004/jnccn.2025.0017
DO - 10.6004/jnccn.2025.0017
M3 - Article
C2 - 40203873
AN - SCOPUS:105002481152
SN - 1540-1405
VL - 23
JO - JNCCN Journal of the National Comprehensive Cancer Network
JF - JNCCN Journal of the National Comprehensive Cancer Network
IS - 4
M1 - e250017
ER -
SDG 3 Good Health and Well-being